Alain Rook, MD
He has conducted seminal studies on the photodynamic therapeutic efficacy of synthetic hypericin in CTCL and psoriasis patients and on its apoptotic activity in malignant cancer cells. Dr. Rook’s research has been supported by the Leukemia and Lymphoma Society, the National Institutes of Health and National Cancer Institute.
He graduated from the University of Michigan with an MD degree. Dr. Rook is Board Certified in Dermatology, Internal Medicine, and Nephrology.